Comments

Akero Therapeutics Stock Guidance

AKRONASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$49.14
0.020.04%
Q4 2024 Earnings were released on Fri Feb 28th, before the market open
Akero Therapeutics (AKRO) ForecastNewsEarningsAkero Therapeutics (AKRO) Options

Guidance

DividendsAnalyst RatingsInsider TradesGovernment TradesShort Interest

Akero Therapeutics Stock Guidance | NASDAQ:AKRO | Benzinga

Akero Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Data brought to you by Benzinga APIs

FAQ

Q

What is the most recent guidance for Akero Therapeutics (AKRO)?

A

There have been no specific sales or earnings guidance reported for Akero Therapeutics in recent months.

Browse guidance and forecast on all stocks.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved